Мақола

Brain scintigrams in metastatic carcinoma

Thomas P. HaynieAssociate Professor of MedicineSatish G. JhingranFellow in Nuclear MedicineMilam E. LeavensClinical Assistant Surgeon (Neurosurgery)T. KonikowskiResearch Associate in Nuclear MedicineMonroe F. JahnsAssistant Professor of Biophysics

Cancerjournal1972en

ABI

Аннотация

A review of clinical experience with two agents used in brain tumor imaging, 203Hg-chlormerodrin and 99mTc-pertechnetate, was made to determine true-positive and false-positive rates for the localization of metastatic brain tumors. We found no significant difference between the two agents in the true-positive rate, 70% and 65%, respectively. False-positive rate also revealed no significant differences, 12% and 5%, respectively. Experience with delayed scans using 99mTc-pertechnetate suggests that true-positive rates may be increased with a longer interval between injection and scan than was employed in most of these patients. Newer radiopharmaceuticals currently under investigation may also offer improved tumor detection.

Мавзулар

Medical Imaging Techniques and Applications Radiopharmaceutical Chemistry and Applications Brain Metastases and Treatment

Идентификаторлар

DOI: 10.1002/1097-0142(197210)30:4<953::aid-cncr2820300415>3.0.co;2-i

Иқтибослар ва манбалар

0 та иқтибос10 та фойдаланилган манба

Кўрсаткичлар — AkademScholar · Тез орада